<DOC>
	<DOCNO>NCT01693614</DOCNO>
	<brief_summary>This phase II study evaluate safety , tolerability efficacy BKM120 patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) , mantle cell lymphoma ( MCL ) follicular lymphoma ( FL ) .</brief_summary>
	<brief_title>Safety Efficacy BKM120 Relapsed Refractory NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Patient histologically confirm diagnosis mantle cell lymphoma , follicular lymphoma , diffuse large B cell lymphoma . 2 . Patient relapse refractory disease receive least one prior therapy . 3 . Patient diffuse large B cell lymphoma receive ineligible autologous allogeneic stem cell transplant . 4 . Patient least one measurable nodal lesion ( ≥2 cm ) accord Cheson criterion ( Cheson 2007 ) . In case patient measurable nodal lesion ≥ 2 cm long axis baseline , patient must least one measurable extranodal lesion . 5 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 6 . Patient adequate bone marrow organ function . 1 . Patient receive previous treatment PI3K inhibitor 2 . Patient evidence graft versus host disease ( GVHD ) . 3 . Patient active history central nervous system ( CNS ) disease . 4 . Patient concurrent malignancy malignancy within 3 year study enrollment ( exception adequately treat basal squamous cell carcinoma nonmelanomatous skin cancer ) . 5 . Patient score ≥ 12 PHQ9 questionnaire . 6 . Patient GAD7 mood scale score ≥ 15 . 7 . Pregnant nursing woman 8 . Patient use highly effective contraception method avoid become pregnant conceive offspring . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diffuse large B-cell lymphoma , Mantle cell lymphoma , Follicular lymphoma , PI3K inhibitor , Non-Hodgkin lymphoma , NHL</keyword>
</DOC>